UCSF Movement Disorders Neurology Research /Support Staff Jill - - PowerPoint PPT Presentation

2/15/2018

New Directions in Movement Disorders

Caroline Tanner, MD, PHD Jill Ostrem, MD UCSF Movement Disorder and Neuromodulation Center Recent Advances in Neurology 2018 UCSF Weill Institute of Neurosciences

UCSF Movement Disorders

Neurosurgery Philip Starr, MD, PhD Paul S. Larson, MD Edward F. Chang, MD Daniel Lim, MD, PhD Krzysztof Bankiewicz, MD, PhD Coralie De Hemptinne, PhD Whitney Chen, PhD Doris Wang, MD, PhD Neuropsychology Caroline Racine Belkoura, PhD Nursing Monica Volz, FNP, MS Karen Merchant, MSN Susan Heath, MS, RN Gina Bringas-Cinco, RN Annie Li Wong, NP Neurology Jill Ostrem, MD Nicholas Galifianakis, MD Caroline Tanner, MD, PhD Marta San Luciano, MD Maya Katz, MD Ian Bledsoe, MD,MS James Maas, MD, PHD Chadwick Christine, MD Michael Aminoff, MD Robert Edwards, MD Ken Nakamura, MD, PhD Alexandra Nelson, MD, PhD Michael Geschwind, MD Amy Viehoever, MD, PhD Nijee Luthra, MD, PhD Cameron Dietiker, MD Fellows Jessica Weinstein, MD Kyle Mitchell, MD Jennifer Choi, MD Ethan Brown, MD Mitra Afshari, MD Melissa Heiry, MD Idit Tamir, MD, PhD Research /Support Staff Sarah Wang, PhD Kristen Dodenhoff, BA Farah Kauser Joncarmen Mergenthaler Janet Allen Shatara Blackmon Yasmeen Gonzalez Jeverly Calaunan Kathleen Comyns, MPH Samantha Betheil, BA Cheryl Meng, MPH Danilo Romero Kanchi Mehta Psychiatry Andrea Seritan, MD Social Work Monica Eisenhardt, LCSW Chaplin Judith Long Physical Therapy Nancy Byl, PT, PhD Heather Bhide, PT

Disclosures

Caroline Tanner, MD, PHD

• An employee of the San Francisco Veterans Affairs Medical Center and the University
• f California – San Francisco.
• Receives grants: the Michael J. Fox Foundation, the Parkinson’s Disease Foundation,

the Department of Defense, BioElectron, Roche/Genentech and the National Institutes of Health,

• Compensation for serving on Data Monitoring Committees: Biotie Therapeutics,

Voyager Therapeutics and Intec Pharma

• Personal fees for consulting: Neurocrine Biosciences, Adamas Therapeutics,

PhotoPharmics , 23andMe and Alexza

Jill Ostrem, MD

• Consultant and speaker: Allergan Inc., Medtronic Inc.
• Educational grant support: Medtronic Inc, Allergan Inc, AbbVie Inc, Boston Scientific

Inc.

• Clinical trial support: Ceregene Inc., St. Jude Medical, Inc, Boston Scientific Inc, Cala

Health Inc, Google Inc

New Direction #1

• Parkinson’s Disease is not one disease

and will be better managed with an individual treatment approach

2/15/2018

5

One Disease or Many? PD Subtypes

jamanetwork.com

PD Genetics

Genetic influence increasingly recognized Monogenic forms (Mendelian inheritance)= mutation in single gene sufficient to cause PD 30% of all familial cases ~5% of sporadic cases Six regions contain genes that conclusively cause PD The cause of PD is multifactorial

• Several genes
• Modifying effects of susceptibility factors
• Environmental exposures
• Gene-environment interactions

7

Penetrance/ Effect Size Age at onset of PD Young-onset Late-onset LRRK2 SNCA VPS35

15-50% ~5%

Parkin DJ-1 PINK1 SNCA

PD Genetics– Targeted Therapies

Gene Mutations Protein/Enzyme Function Age at

• nset

Phenotype Pathology Dominantly inherited last-onset PD SNCA Missense Alpha synuclein- structural brain protein 60 yr (30-80) Levodopa responsive Diffuse lewy bodies SNCA Locus duplication (and triplication) 31-71 yr Levodopa responsive, younger age, rapid progression, autonomic dysfunction, dementia, wide spread Lewy Bodies Diffuse lewy bodies, prominent nigral and hippocampal loss LRRK2 Missense: Arg 1441Cys/Gyl/His; Try1688Cys, Gly2019Ser, IIe2020Thr Polymorphisms, protective haplotypes Leucine-rich repeat kinase 2- enzyme when mutated causes Lewy-body phenotype –increased kinase activity 60 yrs (32-79) Levodopa responsive, Like sporadic PD, slow progression, abduction-addition lower limb tremor, little dementia Brain Stem LB, neurofibrillary tangle or TDP-43 pathology and/or nigral neuronal loss VPS35 Missense: ASP620Asn 53 yrs (40-68) Levodopa responsive tremor-dominant, dyskinesia and dystonia, occasionally dementia Inconclusive- ? No LB Juvenile and early-onset recessively inherited PD PARK2 Numerous missence, exon deletion and duplication mutations Parkin- a ubiquitin-protein ligase involved in protein degradation <45yr (12-58) Levodopa responsive, early dystonia, slow progression, hyperreflexia, dyskinesia, early gait and balance issues, less non-motor Predominantly nigral neuronal loss Occasionally with synuclein

• r tau pathology

PINK1 Misssence: many Rare: locus and exon deletion PTEN-induces putative kinase <45yr (18- 56) Levodopa responsive, akinetic/ridgid postural instability, gait, slow progression, sleep benefit One case with lewy bodies DJ-1 Misense: Glu163lys, Leu 166Pro Exon 1-5 deletion, g.168-185 dup Positive regulator of androgen- receptor dependent transcription <40 yr (24-39) Like PINK-1, rare Unknown

2/15/2018

PD Mechanisms of Disease

Protein trafficking

• ubiquitin/protease system
• alpha-synuclein

Calcium-channel

• apoptosis

Inflammation Oxidative stress Mitochondrial dysfunction

Trinh J and Farrer M Nature Review, 2013.

LRRK2 Mutation

Phenotype

• Like sporadic PD (later onset)
• Variable clinical and pathological

phenotype

• Levodopa responsive
• Slow progression
• Abduction-addition lower limb

tremor

• Little dementia

Video Courtesy of Dr. San Luciano and Darel Ogbonna

• Mutation in the leucine rich repeat kinase 2 (LRRK2) gene (G2019S) is

the greatest known genetic cause of PD

• Most common monogenic cause of PD in Europe and North America
• 30% penetrance
• Mutations seem to heighten the activity of LRRK2 kinase

LRRK2 Treatment Approaches

LRRK2 based treatment

• Inhibitors of LRRK2 kinase activity could potentially be used to

prevent or treat PD Denali Therapeutics

• Completed phase I study in control volunteers in 12/2017.
• Reported 90% inhibition of LRRK2 activity (target engagement)
• Well tolerated
• Also testing a second compound in Phase I study.
• Likely these drugs will move into phase II trial in LRRK2 PD

patients next.

PD and GBA Mutation

GBA mutations cause dysfunction in the glucocerebrosidase (Gcase) protein- leading to build-up of alpha-synuclein More common in Ashkenazi Jewish descent /Gaucher or relative with Gaucher (lipids build up and enlarge organs) 5-10 % of PD patients carry this mutation GBA mutation - 20X increased risk of PD GBA mutations are common but overall chance of PD is still low

Phenotype

• Slightly earlier age of onset
• Initial symptom often

bradykinesia

• More rapid motor disease

progression, more dyskinesia

• More cognitive dysfunction
• Less tremor
• More depression

Video Courtesy of Dr. San Luciano and Darel Ogbonna

2/15/2018

GBA Treatment Approaches

Sanofi / Genzyme

• Small molecule (GZ/SAR402671)

Venglustat -targeting cellular dysfunction in PD patients with a GBA mutation (also for Gaucher Type III disease and Fabry disease)

• Glucosylceramide synthesis inhibitor
• Pre-clinical GBS mutation PD models treated with similar compound had fewer

alpha-synuclein aggregation and did better on memory tests

• Phase II international trial enrolling PD patients with GBA mutations (N=230)
• First industry – sponsored Phase II clinical trial in genetically defined PD

population

Video Courtesy of Dr. Ian Bledsoe Heterozygous carrier of N370S mutation

Mitochondrial Dysfunction in Genetic PD

• Overwhelming evidence implicates

mitochondrial function being compromised in Parkinson’s disease

• Oxidative stress is found in PD tissue

Especially for genetic subtypes:

• Parkin
• PINK1
• DJ-1
• LRKK2
• Energy failure leads to neuronal cell death
• Nigral dopaminergic neurons seem to be

selectively vulnerable to energy failure

• Energy-based therapies have generally failed

in their application in PD

Mitochondrial Based Therapies

Parkin Mutation PD

Parkin- a ubiquitin-protein ligase involved in protein degradation Numerous missense, exon deletion and duplication mutations, No LB? Phenotype: Levodopa responsive, dystonia, akinetic/ridged, postural instability, gait, slow progression, sleep benefit

Video Courtesy of Dr. Nick Galifianakis

DJ-1: Mitochondrial regulation, antioxidative stress, chaperone PARKIN: Mitochondrial autophagy, ubiquitin-protease system PINK1: Mitochondrial serine/threonine-protein kinase, protects against mitochondrial dysregulation LRRK2: modulates mitochondrial dynamics and function

A Phase 2A Safety and Biomarker Study of EPI-589 in Mitochondrial Subtype and Idiopathic Parkinson’s Disease Subjects

Caldwell, 2008

Bioelectron – EPI-589

Phenotype:

• (R)-troloxamide quinone (EPI-589) is a vitamin E

derivative and ORALLY available drug

• Aids in the catalysis of glutathione, an important

antioxidant that aids in reducing oxidative stress

• Glutathione depletion has been linked to

mitochondrial dysfunction

• Being developed for treatment of neurological

diseases characterized by high levels of oxidative stress and mitochondrial pathology (i.e. ALS, PD, HD, mitochondrial diseases)

• Focus on safety and quantifying glutathione cycle

biomarkers

2/15/2018

New Direction #2

• Newer formulations of carbidopa/levodopa

are on the market or in development

Levodopa

• Most effective and widely used treatment in PD
• Dopa decarboxylase (carbidopa) inhibits peripheral LD

metabolism- more levodopa CNS availability (improves tolerability reducing nausea)

• Early PD simple dosing schedules, becomes more

complex in advanced PD

• Short half-life (1.5 hours)
• As PD progresses, conversion of LD to dopamine,

storage, release, becomes unpredictable

• Intermittent/pulsatile release of dopamine in the

striatum, produces changes in the postsynaptic receptors leading to motor complications and dyskinesia (70% after 5 years)

Motor Fluctuations

Typical Clinical Pattern of Wearing Off

Adapted from Hauser RA. Geriatrics. 2006;61:14-20. Symptoms not adequately controlled (“off time”) Symptoms adequately controlled (“on time”) PD Medication PD Medication PD Medication “Wearing off” period Time

Extended Release Carbidopa/Levodopa (Rytary- IPX066) (Impax)

• New oral formulation of CD-LD

(contains both IR and CR levodopa)

• Each Rytary capsule contains CD-

LD (1:4) microbeads designed to dissolve at various rates allowing for release and absorption of LD

• ver a longer timeframe

2/15/2018

Conversion to Rytary

Carbidopa/Levodopa Enteral Suspension Duopa (AbbVie)

• Continuous intraintestinal infusion of C/L gel
• Programmable pump to adjust dose
• Prospective, double-blind, double dummy, double

titration study showed reduction in off time without increase in dyskinesia

• High complication rate, Costly

Practical Considerations

Dose titration:

• Outpatient, but at least ½ day in office to initiate
• Calculate based on current c\l dose
• Infusion usually 16 hours
• Morning dose a bolus
• Continuous dose thereafter with option for extra doses

Return in one week for re-adjustment of dose Monitor B12, B6 (peripheral neuropathy)

• Costs: Est.~ $6000/month
• Patient and caregiver understanding key to

success

• Care of site
• Handling of cassette
• Pump program can be fixed or adjustable
• Adjustable often better efficacy

(Medical Letter 2015)

PD Drugs in Development

New Drug: Other LEVODOPA Formulations

• CVT-301 (Acorda)
• Accordion Pill (Intec Pharma)
• Dopafuse (SynAgile)
• ND0612L “Pump Patch”

(Neuroderm) Neuroprotective agents?

• Inosine
• Isradipine
• Nicotine
• NAC
• Nilotinib
• Monoclonal antibodies to

misfolded alpha-synulean

• Affitope PD01A vaccine

Other DOPAMINE AGONISTS

• Apomorphine infusion (Ago-Go)
• Apomorphine sublingual film (APL-

130277) (Sunovion) Others

• ADX48621-201 (Dipraglurant-IR) (Addex

Therapeutics)

• AVP-923 (dextromethorphan/quinidine)

(Avanir Pharmaceuticals)

• Eltoprazine (Amarantus Bioscience)
• AQW051 (alpha7 nicotinic receptor)

(Novartis)

• Nicotinic receptor agonists in PD

(AstraZeneca)

• Preclinical stage of development
• Candidate drug is already tested for

safety and tolerability in humans

2/15/2018

Carbidopa /Levodopa Inhaled Formulation CVT-301 (AcordaTherapeutics)

• Inhaled formulation of levodopa
• Developed for rapid/reliable relief from debilitating off periods
• Fine powder delivered via a small, plastic inhaler similar to an asthma

inhaler

• Phase III showed safety and efficacy to improve motor function in PD

experiencing OFF periods

• Filed new drug application with FDA 2017
• New levodopa formulation which surface area

expands over time in the stomach to achieve longer half-life

• Used biodegradable polymeric films
• Allows for maximum absorption before leaving

the stomach

• Promising Phase II study results
• Phase II study enrolled and study to be

completed in 2018

Carbidopa/Levodopa Gastro Retentive Formulation Accordion Pill (Intec Pharma delivery system) Continuous Oral Carbidopa Levodopa DopaFuse / OroFuse (SynAgile)

• Continuous delivery of

carbidopa/levopdopa via the mouth

• Device that uses a customized

reusable retainer fitted to the top of the mouth/teeth with a miniature disposable propellant-driven drug pump

• Fresh drug pump each week –

remove to eat

• Phase IIa study showed improved

“off” time compared to regular C/L* Stocchi F, et al. Abstract Movement Disorders Congress 2016

L i q u i d L e v o d o p a S u b c u t a n e o u s C o n t i n u o u s D e l i v e r y ( N e u r o d e r m ) “ P u m p - p a t c h ” ( N D 0 6 1 2 L , N D 0 6 1 2 H , N D 0 6 0 8 0 )

• Levodopa/carbidopa formulation continuously administered subcutaneously

“Pump-patch”

• May reduce or prevent motor complications
• Small device (as big as a credit card) made up of a drug reservoir and a series of

micro-needles (painless) pump the therapy under the skin and into the blood stream

• Phase II study- Significant reduction on off time and well tolerated*
• Phase III study planned

* Olanow W, et al. Abstract Movement Disorders Congress 2017

2/15/2018

Amantadine ER Gocovri (Adamas)

• FDA approved for levodopa induced dyskinesia

(first drug)

• Also some reduction in off time
• Special concentration profile with time: initial

slow rise overnight, highest concentration achieved in the morning and daytime when most useful

• Once-a-day dosing, 137mg QHS for one week

then increase to 274mg QHS

• SE: Hallucinations/ Peripheral Edema

Oertel et al Movement Disorders, 2017.

New Direction #3

• The field of DBS is about to get more

complicated! Historical DBS Considerations – Medtronic Devices

Vim Thalamus Subthalamic Nucleus Globus Pallidus

Single Channel Dual Channel

• Which device?
• Which location?

St Jude Medical/Abbott Infinity DBS System now FDA approved

• FDA approved 2016 for PD and ET
• Constant current device
• BluetoothTM wireless communication
• Upgradeable software option
• Bilateral frequency control
• Communicates with Apple digital devices

(iPad mini/iPod touch)

• Directional lead to allow for current

“steering”

• Not MRI compatible
• Non-rechargable

2/15/2018

Boston Scientific Vercise™ DBS System now FDA approved

• Soon to have Non-rechargeable and rechargeable neurostimulators
• Tablet based programmer
• Current steering and 8 electrode DBS leads
• Directional leads
• Fractional current delivery
• Not MRI Compatible- may change soon?

New DBS directional leads

Traditional Medtronic Lead (Four concentric ring electrodes) Two concentric ring electrodes (outer) Six non-concentric directional electrodes (middle) New leads

New software to localization and visualize shape

• f electrical stimulation field
• Computational modeling / volume of tissue activation (VTA) and

individualized direct programming

35

New Direction #4

• Therapeutics for PD directly target

pathological alpha synuclein are now in clinical trails

2/15/2018

Immunotherapeutic Approach in PD- Anti Alpha-Synuclein

Prevent and promote the clearance of misfolded alpha- synuclein targeting the underlying disease mechanism and slow and ultimately halt the disease process. Monoclonal Antibody Infusion against alpha-synuclein - blocks cell to cell transmission by blocking uptake of misfolded endogenous alpha synuclein

Roche – PRX002

A Phase 2 Study of Anti-α-Synuclein Antibody in Early ParkiNson’s DiseAse

• PRX002 is an INFUSION of a humanized

monoclonal antibody against an epitope on the C-terminus of human α-synuclein

• Aggregated and phosphorylated α-synuclein is

the major component of pathological hallmark lesions in…

• PD: Lewy bodies, Lewy neurites
• MSA: glial cytoplasmic inclusions
• Antibody has a high affinity for pathologic

forms of α-synuclein consisting of oligomers and fibrils, ultimately preventing propagation and neuronal cell death

• ENROLLING EARLY-PD PATIENTS (within 2

years from dx, H&Y <= 2, MAO-I-treated only, not anticipated to start a new dopaminergic rx for 1 year)

Synaptic/Neuronal Loss and Pathological Spread Antibodies neutralize and clear pathogenic

• synuclein
• F. Hoffman-La Roche, Ltd.

Aggregated, extracellular Syn

Biogen – BIIB054

• BIIB054 is an INFUSION of a humanized

monoclonal antibody against an epitope

• n the N-terminus of human α-synuclein
• Antibody has a high affinity for

aggregated pathological forms of α- synuclein as well, to ultimately prevent propagation and neuronal cell death

• Adopted by the Parkinson’s Study Group
• ENROLLING EARLY-PD PATIENTS (within

3 years from dx, H&Y <= 2.5, UNTREATED for at least 12 weeks and not anticipated to start a dopaminergic rx for 6 months) A Phase 2a Study of the Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects with Parkinson’s Disease

Immunotherapeutic Approach in PD- Anti Alpha-Synuclein

Vaccine development against alpha-synuclein

• AFFiRiS First in human trial to assess the safety and tolerability

(Europe) - Phase IA study showed positive safety and toxicity profile (N=32)

• Multiple (4) subcutaneous vaccinations with two doses were tested/

Patients developed intended alpha-synuclein- antibodies

• Multiple phase Ib trials ongoing/ Randomized to low or high booster

immunizations Preventing Toxic Protein Aggregation

• Neuropore/UCB – NPT200-11 – Binds to alpha-synuclein and blocks
• accumulation. Planning Phase Ib study in Europe
• Proclara/Neurophage – NPT088 – Binds to alpha-synuclein and

amyloid- beta and tau. ALZ 1st and next would be PD

2/15/2018

New Direction #5

• Evaluate for Falls in PD. Very common

and multifactorial in many patients.

Falls in the Elderly

Simon Fraser University Video Footage of Falls https://www.youtube.com/watch?v=Z3e1Xvnj8Wo

PD Postural Instability

Consequences of Falls

Falls  Fractures

• Reduced mobility
• Prolonged hospital stay
• Prolonged recovery after surgical repair
• Increased placement outside of home
• Increased mortality

Falls  Head injuries

• Concussion, subdural, etc.  CNS injury
• Reduced cognitive function, reduced mobility, seizures
• Prolonged hospital stay
• Increased placement outside of home
• Increased mortality

2/15/2018

Osteoporosis & Parkinson’s Disease

Torsney et al, 2012

Prevention

Falls Prevention

• Environmental modification - remove obstacles,

correct footwear & eyeglasses, improve lighting, etc.

• Avoid hypnosedatives
• Physical therapy
• Tai chi, dance
• Monitor & treat Orthostatic Hypotension

Fracture Prevention

• Reduce osteoporosis/osteopenia (vit.D, Calcium, bis-

phosphonates)

• Reduce falls
• “Learn how to fall”

Northera (Droxidopa capsules)

• Treatment for neurogenic orthostatic hypotension associated

with PD, MSA, and pure autonomic failure

• Converted to norepinephrine and causes vasoconstriction
• Recently FDA approved (Chelsea Therapeutics)
• Dose 100mg TID (am, midday, late

afternoon, >3hr before bedtime)

• Titrate up by 100mg every other

day –max dose 600mg TID

• Box warning for risk of supine

hypertension

New Direction #6

• It can be helpful to obtain a DatScan in

these clinical situations:

2/15/2018

DatScan Mechanism & Indications

INDICATIONS AND USAGE* DaTscan is a radiopharmaceutical indicated for striatal dopamine transporter visualization using single photon emission computed tomography (SPECT) brain imaging to assist in the evaluation of adult patients with suspected Parkinsonian syndromes (PS). In these patients, DaTscan may be used to help differentiate essential tremor from tremor due to PS (idiopathic Parkinson’s disease, multiple system atrophy and progressive supranuclear palsy). DaTscan is an adjunct to other diagnostic evaluations. *Bajal, 2013; FDA Product Label

Case 1

• 68 yr old retired left handed pharmacist
• History of GERD with increasing severity in recent months 

taking metoclopramide , recently increased from 10 mg. TID to 15 mg. QID with good control of symptoms

• Has noticed sense of muscular stiffness, increased fatigue,
• ccasionally a tremor at rest, affecting both upper

extremities, more bothersome on the left side

• Referred to neurologist
• Exam: Mild bilateral bradykinesia, intermittent resting tremor

left > right, slightly stooped posture, small steps, reduced arm swing bilaterally

• Gastroenterologist reluctant to discontinue metoclopramide

given increased symptoms

• Referred for a SPECT scan

Case 1 SPECT with DatSCAN (123I-Ioflupane)

Normal scan

COMMENT: Metoclopramide blocks striatal dopamine receptors and can produce drug-induced parkinsonism. Symptoms resolve gradually after stopping drug treatment.

Case 2

• 78 year old retired high school English teacher
• Brought to office by daughter
• Recent history of fearfulness, believing there are intruders

in his home; called exterminator 4 times in 2 months to remove rats; loss of interest in reading, golfing; fell 2 weeks ago

• Lifelong history of “shakiness” on and off throughout adult

life, particularly bothersome during public speaking; never treated

• Exam: Oriented to person, 2 years off on date, difficulty

copying figures and generating lists of words; Mild postural tremor bilaterally; mild right hand resting tremor, reduced right arm swing, stooped posture, pull test: retropulsion 4- 5 steps

2/15/2018

Case 2 SPECT with DaTSCAN (123I-Ioflupane)

Abnormal scan

Diagnostic accuracy of 123I-FP-CIT SPECT in possible dementia with Lewy bodies

O’Brien, British J Psychiatry 2009

• Dopamine transporter imaging can distinguish Dementia with Lewy Bodies from

Alzheimer’s Disease: 100% of clinical AD at 12 months had normal scans at baseline

Case 2 Comment:

• 20 patients with a clinical diagnosis of DLB or other dementia & Datscan at diagnosis
• Follow-up with detailed neuropathological autopsy
• 8 DLB, 9 AD, 3 other diagnoses
• Sensitivity initial clinical diagnosis of DLB was 75%, specificity was 42%
• DatSCAN sensitivity was 88% and specificity was 100%
• Conclusion: FP-CIT SPECT scans substantially enhanced the accuracy of diagnosis of DLB by

comparison with clinical criteria alone

Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy

WalkerJ Neurol Neurosurg Psychiatry 2007

Dopamine Transporter Imaging in Autopsy-Confirmed Parkinson’s Disease and Multiple System Atrophy

Laura D. Perju-Dumbrava, Movement Disorders, 2012

• Abnormal imaging in

both PD and MSA

• Asymmetry possibly

greater in MSA

• DATSCAN cannot

differentiate

Case 3- ET

• A 55 year old right handed woman, works as a jewelry artist
• Recent sense of slight loss of fine movement dexterity,

especially in right hand

• Fatigue and tremor of right hand more than the left hand
• Neurologist examination:

– ? right upper extremity rigidity, possible cogwheel phenomenon – mild bradykinesia throughout – fine tremor in the hands (right>left) – tremor at rest and with posture – normal gait

• Referred to observational trial in early PD
• Referred for baseline DatScan

2/15/2018

Case 4 : SPECT with DATscan (123I-Ioflupane)

Normal Scan

New Direction #7

• Toxicant Exposure and Parkinson’s

Disease

• Ask about military service!

Vietnam Veteran

Used defoliant agent orange

• 2009: Agent Orange Linked to Parkinson's Disease

established service-connection:

• Certain Vietnam Veterans may be eligible for:

disability compensation and health care benefits.

Agent Orange & Parkinson’s Disease Risk

2,4-D 2,4,5-T

2,3,7,8 tetrachlorodibenzodioxin

Operation Ranch Hand: 1962-1971 20 x 106 gallons Agent Orange

2/15/2018

Camp Lejeune N.C.

Sources of exposure: Drinking water, bathing, Inhalation, swimming, recreation History: 1953-1985 - Water contaminated with TCE & PCE (i.e., PERC) 1980 – Contaminants discovered 1987- Wells closed 1989 - EPA Superfund 500,000 – 1 million exposed Military: Marines, National Guard, reservists Civilian: Family members, employees Exposure levels:

• Est. monthly median (max. mean) ug/L:

PCE: 85 (158); TCE: 366 (783)

• vs. US max. contaminant level: 5 ug/l
• Dept. of Veterans Affairs 2017
• 30 or more days of service
• Entitled to benefits

New Direction #8

• There are new treatments for tardive dyskinesia
• Tardive dyskinesia is an uncontrolled movement

that is associated with prolonged use of dopamine receptor blocking agents (DRBAs) for at least a few months

Tardive Dyskinesia

Treatment of TD: American Psychiatric Association (APA)

American Psychiatric Association (APA)1

• TD treatment recommendations from

Schizophrenia Practice Guideline (last published in 2004): – Use second-generation antipsychotics due to “decreased risk of extrapyramidal side effects and TD” – For TD, switch to a second-generation antipsychotic or reduce first-generation dose – Perform a baseline assessment of abnormal involuntary movements with

• ngoing monitoring:
• First-generation antipsychotics: Every 6

months (3 months for high-risk patients)

• Second-generation antipsychotics: Every 12

months (6 months for high-risk patients)

APA Guideline Watch2

• Updated 2009
• No specific TD recommendations
• “The distinction between first- and second-

generation antipsychotics appears to have limited clinical utility”

• 1. Lehman AF, et al. Am J Psychiatry. 2004;161(2 Suppl):1-56. 2. American Psychiatric Association (APA), et al. Guideline Watch (September 2009).

http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/schizophrenia-watch.pdf. Accessed August 2017.

2/15/2018

Prospective Survey of TD in Psychiatric Outpatients

• Preliminary Findings

20% Schizophrenia 18% Schizoaffective disorder 61% Mood disorder (Anxiety 37%, Bipolar 29%, Major depressive disorder 22%) 1% Other First and second generation antipsychotics associated with TD Incidence rates in patients over age 55

• 25% after 1 year
• 34% after 2 years
• 53% after 3 years

Dopamine-Depleting Drugs

Reserpine and Tetrabenazine (TBZ)  Inhibit vesicular monoamine transporter (VMAT) at the presynaptic membrane of the nerve terminals  Expose monoamines to monoamine oxidase  Depletion of synaptic pool of monoamines

Reserpine:

• Slower onset and prolonged duration of

effect

• Inhibits both VMAT1 and VMAT2
• Side effects of depression, orthostatic

hypotension and GI side effects TBZ:

• Quicker onset and shorter duration
• f effect
• Inhibits only VMAT2
• Side effects of depression, lethargy,

parkinsonism, akathisia

Valbenazine and Deutetrabenazine

Valbenazine Deutetrabenazine Dosing Dosed once a day Dosed multiple times a day and with multiple tablets Titration Requires no titration and 1 week to reach the recommended dose Typically requires titration, often over the course of several weeks Food Can be taken with or without food Needs to be taken with food Selectivity A selective VMAT2 inhibitor with no appreciable binding affinity for dopaminergic (including D2) or serotonergic receptors Not a selective VMAT2 inhibitor EKG

• Doesn't require an EKG to start

treatment

• For patients at increased risk of a

prolonged QT interval, assess the QT interval before increasing the dosage

• For patients at risk for QT

prolongation, assess the QT interval before and after increasing total deutetrabenazine dosage above 24 mg per day

• Assess the QTc interval before and

after increasing the dose of other meds known to prolong QTc

UCSF Movement Disorders and Neuromodulation Center UCSF Mt Zion Campus 1635 Divisadero Street, Suite 520, San Francisco, CA 94115 Referrals:

• Clinical Consultations: 415-353-2311 (phone); 415-353-9060 (fax)
• Clinical Trials: 415-353-8328; (Danilo Romero)

Danilo.Romero@ucsf.edu